J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nath, R.
Right arrow Articles by Mendelson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nath, R.
Right arrow Articles by Mendelson, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations

RP Nath, RA Upton, ET Everhart, P Cheung, P Shwonek, RT Jones, and JE Mendelson

Buprenorphine is an effective new treatment for opiate dependence. This study compared the bioavailability of buprenorphine from a tablet to that from a reference solution. Six men experienced with, but not dependent on, opiates (DSM-III-R) were each administered 7.7 mg of buprenorphine in liquid form and 8 mg in tablet form 1 week apart in a balanced crossover design. Plasma levels were measured by electron capture capillary gas chromatography (GC), and concentration-time curves were constructed. Pharmacokinetic data were analyzed by analysis of variance. The bioavailability from the tablet was approximately 50% that from the liquid and was not affected by saliva pH. Lower bioavailability from the tablet may be due to slow dissolution.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
D. A. Ciraulo, R. J. Hitzemann, E. Somoza, C. M. Knapp, J. Rotrosen, O. Sarid-Segal, A. M. Ciraulo, D. J. Greenblatt, and C. N. Chiang
Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials
J. Clin. Pharmacol., February 1, 2006; 46(2): 179 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. J. Kreek, G. Bart, C. Lilly, K. S. Laforge, and D. A. Nielsen
Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Pharmacol. Rev., March 1, 2005; 57(1): 1 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. S. Schottenfeld, M. C. Chawarski, J. R. Pakes, M. V. Pantalon, K. M. Carroll, and T. R. Kosten
Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence
Am J Psychiatry, February 1, 2005; 162(2): 340 - 349.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Fudala, T. P. Bridge, S. Herbert, W. O. Williford, C. N. Chiang, K. Jones, J. Collins, D. Raisch, P. Casadonte, R. J. Goldsmith, et al.
Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
N. Engl. J. Med., September 4, 2003; 349(10): 949 - 958.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology